Signature Diagnostics licenses gene software from Genedata for colorectal cancer prognosis test
This article was originally published in Clinica
In an effort to bring to market its prognostic test for colorectal cancer, Signature Diagnostics has licensed gene-profiling software from bioinformatics firm Genedata.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.